As previously announced, ISR has a Phase IIa study of HIV-infected patients on anti-retroviral therapy (ART), where patients will be randomized to receive GnRH agonist (ISR048) in addition to ART, or ART alone. The first patient is now enrolled.

ISR’s Phase IIa clinical study, ISR-003, is conducted at the Karolinska University Hospital Huddinge and at the South Hospital in Stockholm, SÖS. The study is composed of two arms with a total of 26+26 patients to be randomized into ART+ISR048 or to ART alone in the control group. Patients will be treated for 3 months and then followed for an additional 3 months with the major readout HIV DNA reservoirs. The study is expected to be ending in Q2 2019.

“We are excited to have started enrolment of patients. The study is unique, where ISR048s capacity to eradicate HIV virus carrying cells will be evaluated”, comments Ola Winqvist, CEO of ISR.

For more information, please contact:
Ola Winqvist
CEO, ISR Immune System Regulation Holding AB (publ)
Email: [email protected] 
Phone: +46 (0) 70 5427939

About ISR Immune System Regulation Holding AB (publ)
ISR is an innovation-driven drug development company in immunotherapy. The company focuses on clinical and preclinical research aimed at developing a broad spectrum antiviral therapy platform within immunopreventive drugs. Erik Penser Bank is the company's Certified Adviser and is available at 08-463 80 00.

www.israb.se   

This information is such information that ISR Immune System Regulation Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on 20 September 2018; 15.04 CET. 

Tags:

Powered by WPeMatico